Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-08-01 / Melanoma Res 2021 08;31(4):378-388Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma /von 2021-07-19 / Sci Rep 2021 Jul;11(1):14661A Bayesian network meta-analysis of comparison of cancer therapeutic vaccines for melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-06-29 / J Eur Acad Dermatol Venereol 2021 Oct;35(10):1976-1986Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials
/in Dendritic Cells, International Publications, Malignant Melanoma, Malignant Pleural Mesothelioma /von 2021-05-19 / Vaccines (Basel) 2021 May;9(5)Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-05-12 / Cancer Med 2021 Jul;10(13):4302-4311A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-02-27 / Ann Surg Oncol 2021 Oct;28(11):6126-6137ASO Author Reflections: The Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine for Advanced-Stage Melanoma: Reflection on Personalized Cancer Vaccination
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-02-26 / Ann Surg Oncol 2021 10;28(11):6138-6139Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2020-04-21 / J Transl Med 2020 04;18(1):176TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma /von 2020-02-01 / J Immunother Cancer 2020 02;8(1)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus
- Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
- A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma